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Treatment for fragile X syndrome and related autism spectrum disorders has long been thought to be
effective only during a narrow window early in development. In this issue of Neuron, Michalon et al. (2012)
dispel this myth.We frequently hear that we are at the cusp
of realizing the promise of molecular
medicine. Nowhere is that promise closer
to being realized than in the case of fragile
X syndrome (FXS). FXS is now considered
the gold standard for neurodevelopmen-
tal research because it has been barely
20 years from the identification of the
gene responsible for the disorder to a
putative molecular mechanism, resulting
in multiple drugs undergoing clinical trials
for treatment of patients. However, a
concern of clinicians and hopeful parents
has been ‘‘what if it’s too late’’? Autism
and related disorders such as FXS always
have been thought to be irreversibly set
within a critical window during early child-
hood development between birth and
3 years of age. Often times, by the time
FXS is diagnosed unambiguously, that
window already has passed, which limits
intervention options considerably. In the
current issue of Neuron, Michalon et al.
(2012) offer a bright ray of hope by com-
prehensively demonstrating the reversal
of a wide variety of FXS phenotypes in
adult mice with CTEP, a new selective
antagonist of mGluR5 (Figure 1).
One of the most enduring hypotheses
in FXS research has been the ‘‘mGluR
theory,’’ which posits that many abnor-
malities associated with FXS are caused
by excessive metabotropic glutamate re-
ceptor 5 (mGluR5) signaling. This exces-
sive signaling results in exaggerated pro-
tein synthesis, which triggers an array of
abnormal synaptic plasticity and behav-
iors (Bear et al., 2004). The theory was
derived from basic science studies of
hippocampal synaptic plasticity (Huber
et al., 2002) that showed enhanced
metabotropic glutamate receptor-depen-
dent long-term depression (mGluR-LTD)in FXS mice. Major support for the mGluR
theory of FXS came soon thereafter from
two sets of findings, the first of which
was in Drosophila (McBride et al., 2005)
and demonstrated that deletion of dfmr1
gene produced synaptic and behavioral
deficits that could be counteracted by
mGluR antagonists. The second study
was the seminal paper of Do¨len et al.
(2007) that reported a wide variety of
molecular, cellular, and behavioral pheno-
types in FXS model mice could be cor-
rected with a 50% genetic reduction of
mGluR5 expression. This study provided
a proof of principle and made mGluR5
a bona fide target for FXS therapy that
ramped up the search for high-fidelity
blockers of this receptor.
MPEP and fenobam aremGluR5 antag-
onists that have been available for several
years. Although both compounds effi-
ciently block receptor activity, the down-
side is that they are extremely short-
acting, with a half-life of approximately
15 min in the brain. Even before the
genetic studies firmly established the
viability of themGluR theory, it was shown
that acute administration of MPEP to FXS
model mice could reduce hyperactivity in
an open field arena and abolish suscepti-
bility to audiogenic seizures (Krueger and
Bear, 2011). However, chronic MPEP
administration was not a treatment option
for individuals with FXS because its short
half-life precluded extended receptor
blockade and increased the likelihood of
‘‘yo-yo-ing’’ mGluR signaling when the
drug was cleared. Nevertheless, valuable
information on pharmacological blockade
of mGluR system was gleaned through
these and several other studies. Daily
injections of MPEP and a GluR1 antag-
onist JNJ16259685 showed that theyNeurwere effective in alleviating repetitive
behaviors and enhanced motor learning
in FXSmice (Thomas et al., 2012). In addi-
tion, MPEP has been useful in dissecting
the molecular pathways disrupted in
FXS, which include dendritic spine ab-
normalities, expression of LTD through
AMPAR trafficking, and neocortical long-
term potentiation, to name just a few
(Krueger and Bear, 2011). However, the
bigger problem still remained. If one could
not study effects of the long-term block-
ade of mGluR5 signaling, treatments
based on mGluR theory would remain
a distant dream. That was until, CTEP.
Michalon et al. (2012) used CTEP,
a recently launched negative allosteric
inhibitor of mGluR5 with inverse agonist
properties, which unlike previous mGluR5
antagonists, has extremely long receptor
occupancy, with a half-life of 18 hr (Linde-
mann et al., 2011). A single dose of CTEP
administered every 48 hr, achieved unin-
terrupted mean receptor occupancy of
81%. What makes CTEP even more
attractive is that unlike MPEP, it can be
provided orally. The authors found that
FXS model mice treated with a single
dose of CTEP exhibited normal levels
of brain protein synthesis, normal ex-
pression of mGluR-dependent LTD, and
protection against audiogenic seizures.
Longer treatment of the FXS mice with
CTEP rectified certain cognitive deficits,
dendritic abnormalities in the visual cortex
and elevated ERK and mTOR signaling in
the cortex. Intriguingly, they also ob-
served a partial correction of macro-or-
chidism, demonstrating for the first time
the involvement of mGluRs in this periph-
eral FXS phenotype. This report is also
notable for the inclusion of a section
describing how well the mice toleratedon 74, April 12, 2012 ª2012 Elsevier Inc. 1
Figure 1. CTEP Reverses Phenotypes in FXS Mice after the Critical Developmental Window
(A) Normal neuronal development in the presence of a functional Fmr1 gene.
(B) FXS occurs due to hypermethylation of the 50 end of Fmr1 gene, resulting in transcriptional silencing
and the subsequent loss of fragile mental retardation protein (FMRP). The lack of FMRP is widely thought
to alter synaptic plasticity and circuits critical for pre- and early postnatal stages of brain development,
otherwise known as the ‘‘critical developmental window.’’ This altered development causes deficits in
the cognitive capabilities of individuals afflicted with FXS. Earlier theories supported the notion that effec-
tive treatment for developmental disorders such as FXS could only occur during the critical developmental
window, after which the brain would be hard wired. In the current issue of Neuron, Michalon et al. (2012)
show that administration of CTEP, which blocks mGluR5 signaling after the window, can ameliorate FXS
phenotypes.
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Previewsthe chronic treatment of CTEP for 4 and
17 weeks. The authors found a minimal
reduction in body weight gain and a small
reduction in grip strength in CTEP-treated
mice. The lack of major side effects
bolsters the claims that CTEP should be
the inhibitor of choice for mGluR5 target-
ing in FXS. A crucial litmus test that
remains for CTEP is to determine whether
it improves the social-interaction defects
that form a major part of the cognitive
problems associated with autism spec-
trum disorder (ASD). It is well established
that 50%–60% of all FXS patients display
symptoms of ASD (Hagerman et al.,
2011).
The groundbreaking finding in the study
ofMichalonet al. (2012)was the reversal of
phenotypes in FXS mice at an age when
brain maturation is mostly complete.
Developmental disorders by their very
nature alter the course of proper neuronal
and brain growth via alterations in either
signaling or cellular processes that inter-
fere with timely plasticity and circuit
construction. The silencing of genes
such as FMR1 starts impacting patients
from very early stages of development.
Thus, the debate has been whether the2 Neuron 74, April 12, 2012 ª2012 Elsevier Inaberrant plasticity and circuits that have
been established quite early in postnatal
life with little room for modification or
whether there is residual plasticity in these
circuits that can then be tweaked with
pharmacological interventions. Because
most diagnoses for developmental disor-
ders are done after substantial and unde-
niable cognitive deficits are observed
(1–3 years of age), this issue has hadgrave
implications for any pharmacological-
based therapies. Previous studies of FXS
and Rett syndrome model mice demon-
strated that postdevelopmental interven-
tions could correct an array of abnormali-
ties that would have been predicted
due to aberrant brain development, but
these studies were based on genetic
approaches (Hayashi et al., 2007; Guy
et al., 2007). The big question remained
whether a pharmacological regimen also
could correct diverse brain abnormalities
in amousemodel of FXS. Aprevious study
showed that 2 weeks of MPEP treatment
rescued aberrant dendritic morphology
in FXS mice, but only when treatment
started at birth and not in older mice (Su
et al., 2011). In contrast, CTEP shows
promise in not only reversingdysregulatedc.mGluR5 signaling, but also in reversing
circuit-level disruptions, which is reflected
in the amelioration of abnormal behaviors
displayed by the FXSmice. Thus, neuronal
circuitry in FXS, and perhaps related
developmental disorders associated with
autism, are not ‘‘hardwired’’ during devel-
opment but may differ because of altered
signaling that can be corrected even in
adulthood. This body of work not only
emphatically answers a key concern in
the field, but also raises the bar for assess-
ing the efficacy of other candidate mole-
cules (AFQ056 from Novartis, RO4917523
from Roche, and STX209 from Seaside
Therapeutics) that are either undergoing
or have completed clinical trials, with the
FXS community anxiously awaiting results
(http://www.clinicaltrials.gov).
According to a recently published
screen, FMRP associates with more than
800 mRNA molecules (Darnell et al.,
2011). Only a fraction of the protein pro-
ducts of these mRNAs are involved in
mGluR signaling, with the highest number
being related to broad-spectrum GTPase
signaling. In addition, the role of FMRP in
nonneuronal cells, where it is abundant
during prenatal development, is not well
understood (Hinds et al., 1993). Therefore,
there likely are limits to the applicability of
themGluR theory as the sole, causal basis
of FXS. Another enduring phenomenon of
FXS has been elevated systemic rates of
protein synthesis and deviant signaling
that impacts translational control (Liu-
Yesucevitz et al., 2011). It will be impor-
tant to comprehensively assess whether
CTEP can reset the abnormal translational
control observed in FXS.
In closing, although CTEP may not be
the panacea for all of the ills of FXS, it is
a major step forward toward a viable
therapy for FXS. In addition, the studies
of Michalon et al. (2012) are an excellent
example of the preclinical/translational
studies that are bridging the gulf between
the foundational work of basic, mecha-
nistic science and viable clinical therapies
for brain disorders, thereby realizing the
promise of molecular medicine.REFERENCES
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Axonal target-derived BMPand neurotrophin signaling are both known to regulate neuronal gene expression,
differentiation, and axon growth. In this issue of Neuron, Ji and Jaffrey (2012) discovered that BMP-signaling
endosomes depend on BDNF-induced axonal synthesis of SMADs to retrogradely regulate transcription
in developing trigeminal neurons, providing a mechanism of integrating the two target-derived signals.During nervous system development,
axonal target-derived signals can induce
transcriptional changes which are essen-
tial for neuronal differentiation and correct
assembly of neural circuits. The rodent
trigeminal sensory system has served
as an excellent model to study such
processes. Cutaneous sensory informa-
tion from three distinct facial regions is
transmitted to the brain by the three
branches of the trigeminal ganglion:
ophthalmic (Op), maxillary (Mx), and
mandibular (Md) branches (Figure 1A). A
number of facial target-derived signals
have been shown to regulate different
aspects of the specification, peripheral
axon growth, central axon projection,
and survival of developing trigeminal
sensory neurons (Davies, 1997; O’Connor
and Tessier-Lavigne, 1999; Hodge et al.,
2007; da Silva et al., 2011). Two factors
in particular, brain-derived neurotrophicfactor (BDNF) and bone morphogenic
protein 4 (BMP4), have been the focus of
recent study, including a paper in this
issue of Neuron from Ji and Jaffrey
(2012). In early embryonic development,
between embryonic days E10 and E12,
BDNF is expressed by both the
ophthalmic and maxillary targets as well
as the corresponding pathway mesen-
chyme, and it serves as one of the ‘‘che-
moattractants’’ that attract the axon
outgrowth of trigeminal peripheral axons
(Figure 1A; O’Connor and Tessier-
Lavigne, 1999). After initial axon exten-
sion, BMP4, which is also selectively
expressed by epidermis in the ophthalmic
and maxillary regions at these stages,
retrogradely signals to trigeminal neurons
and induces spatially patterned expres-
sions of several transcription factors
along the dorsoventral axis of the trigem-
inal ganglion (Hodge et al., 2007). Onesuch BMP4-retrograde signaling induced
gene is Tbx3 (Figure 1A).
The intracellular mechanisms that
mediate this BMP4-retrograde signal in
trigeminal neurons have been unclear. Ji
and Jaffrey (2012) describe an interesting
union between BDNF-induced axonal
translation of SMADs (which are effectors
carrying out the BMP transcriptional
signaling) and axon-derived BMP4-sig-
naling endosomes that together mediate
the retrograde specification of trigeminal
neurons (summarized in Figure 1B).
Using microfluidic chambers for com-
partmentalized cultures and separate
manipulations of trigeminal neuron cell
bodies versus axons, the authors estab-
lished that adding BMP4 to the axons
resulted in the appearance of phos-
phorylated-SMAD1/5/8 (pSMADs) within
15 min and Tbx3 gene transcription within
4 hr in the neuronal cell bodies. To showon 74, April 12, 2012 ª2012 Elsevier Inc. 3
